BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 32370988)

  • 1. MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1.
    Su C; Cheng X; Li Y; Han Y; Song X; Yu D; Cao X; Liu Z
    Cancer Med; 2018 Jun; 7(6):2485-2503. PubMed ID: 29663730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2.
    Yu H; Xu X; Zhu L; Chen S; He J
    J Cell Mol Med; 2024 Apr; 28(8):e18216. PubMed ID: 38652219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBM15-Mediated N6-Methyl Adenosine (m6A) Modification of EZH2 Drives the Epithelial-Mesenchymal Transition of Cervical Cancer.
    Wang R; Tan W
    Crit Rev Eukaryot Gene Expr; 2024; 34(5):15-29. PubMed ID: 38842201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA (miR)-124: A Promising Therapeutic Gateway for Oncology.
    Gourishetti K; Balaji Easwaran V; Mostakim Y; Ranganath Pai KS; Bhere D
    Biology (Basel); 2023 Jun; 12(7):. PubMed ID: 37508353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long and short non-coding RNAs modulating EZH2 signaling in cancer.
    Mirzaei S; Gholami MH; Hushmandi K; Hashemi F; Zabolian A; Canadas I; Zarrabi A; Nabavi N; Aref AR; Crea F; Wang Y; Ashrafizadeh M; Kumar AP
    J Hematol Oncol; 2022 Mar; 15(1):18. PubMed ID: 35236381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Suppressive Effects of miR-124 and Its Function in Neuronal Development.
    Sanuki R; Yamamura T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological and biological importance of EZH2 signaling in lung cancer.
    Entezari M; Taheriazam A; Paskeh MDA; Sabouni E; Zandieh MA; Aboutalebi M; Kakavand A; Rezaei S; Hejazi ES; Saebfar H; Salimimoghadam S; Mirzaei S; Hashemi M; Samarghandian S
    Biomed Pharmacother; 2023 Apr; 160():114313. PubMed ID: 36738498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2.
    Zhu D; Gu L; Li Z; Jin W; Lu Q; Ren T
    Pathol Res Pract; 2019 May; 215(5):861-872. PubMed ID: 30712885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulated miR-144-3p contributes to progression of lung adenocarcinoma through elevating the expression of EZH2.
    Liu C; Yang Z; Deng Z; Zhou Y; Gong Q; Zhao R; Chen T
    Cancer Med; 2018 Nov; 7(11):5554-5566. PubMed ID: 30280514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1.
    Xu L; Sun HB; Xu ZN; Han XL; Yin YY; Zheng Y; Zhao Y; Wang ZX
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7978-7988. PubMed ID: 31599423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-21-5p promotes lung adenocarcinoma cell proliferation, migration and invasion via targeting WWC2.
    Wang G; Zhou Y; Chen W; Yang Y; Ye J; Ou H; Wu H
    Cancer Biomark; 2020; 28(4):549-559. PubMed ID: 32623387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased miR-124 contributes to the epithelial-mesenchymal transition phenotype formation of lung adenocarcinoma cells via targeting enhancer of zeste homolog 2.
    Wu J; Li L; Zhang Y; Zhu J
    Pathol Res Pract; 2020 Jun; 216(6):152976. PubMed ID: 32370988
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.